Eating Away at Antibiotic Resistance – Is Phage Therapy Our Future?
Article Sidebar
Main Article Content
Abstract
This editorial provides a brief background on over a century of research on bacteriophages, which led to the inaugural 2025 Conference on Bacteriophages: Biology, Dynamics, and Therapeutics, supported by the IAS–USA. A summary of this meeting is included in this issue of Pathogens and Immunity and emphasizes the promise of phage therapy.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Pathogens and Immunity abides by Creative Commons BY 4.0:
http://creativecommons.org/licenses/by/4.0/
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.
References
1. Elshazly A, Russell DA, Hatfull GF, Schooley RT, Bollyky PL, Pourtois JD, Freeman KG. Meeting Summary for 2025 Conference on Bacteriophages: Biology, Dynamics, and Therapeutics. Pathog Immun. 2026;11(1). doi: 10.20411/pai.v11i1.942.
2. Zagaliotis P, Michalik-Provasek J, Gill JJ, Walsh TJ. Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans. Pathog Immun. 2022;7(2):1-45. doi: 10.20411/pai.v7i2.516. PubMed PMID: 36320594; PMCID: PMC9596135.